| 1052 |
Peri-Stenotic Stagnation Associates With Red Blood Cell-Rich Thrombi, Linked to Stroke Recurrence and Lesion Volume.
|
2026-02-27 |
63 |
| 1051 |
Microvascular and Macrovascular Cerebral Disease Profiles and Their Association With Cognitive Abilities: A Cross-Sectional Clinical Pathological Study.
|
2026-02-27 |
53 |
| 1050 |
Longitudinal Trajectories of Brain Health Risk Factors Measured by the Brain Care Score and Risk of Stroke, Dementia, and Depression.
|
2026-02-27 |
53 |
| 1049 |
Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association.
|
2026-02-03 |
217 |
| 1048 |
Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.
|
2026-02-03 |
181 |
| 1047 |
Switching From Aspirin Monotherapy After Noncardioembolic Stroke: A Systematic Review and Network Meta-Analysis.
|
2026-02-03 |
208 |
| 1046 |
Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial
|
2026-01-02 |
273 |
| 1045 |
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA)
|
2026-01-02 |
282 |
| 1044 |
Intravenous Thrombolysis Use in the Late Time Window Before Interhospital Transfer for Thrombectomy
|
2026-01-02 |
452 |
| 1043 |
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
|
2025-11-27 |
888 |
| 1042 |
Stroke Mechanism and Severity After Left Atrial Appendage Occlusion: Insights From the LAAOS III Randomized Clinical Trial
|
2025-11-27 |
387 |
| 1041 |
Impaired Perfusion and Early Ischemic Stroke Recurrence in Symptomatic Intracranial Atherosclerosis: BIORISK ICAS Study
|
2025-11-27 |
368 |
| 1040 |
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.
|
2025-10-31 |
513 |
| 1039 |
Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial.
|
2025-10-31 |
413 |
| 1038 |
Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial (ATIS-NVAF).
|
2025-10-31 |
390 |
HOME
LOGIN
